arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

BioNexus Gene Lab Corp

BGLC
$1.58 ▲ +0.26 (+19.70%) at close
Healthcare ·Services-Medical Laboratories ·USServices-Medical Laboratories
34 Visible periods
22 Metrics
Peer-ranked Benchmarks
Price Chart
16
Health
Poor
Bearish
auto_awesome

Analytical Summary

BioNexus Gene Lab Corp faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap
Dividend Yield
Revenue Growth -98.9%
Op. Margin None
ROIC -6.7%
FCF / Share
Trailing P/E
Price / Book 0.5x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

34-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$22.84K
↓ -98.9%
Net Income Profit after all expenses
$-543.58K
↑ +12.8%
Operating Margin Operating profit as % of sales
-213.5%
↓ -673.1% 6th
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
7
Returns
21
Financial Health
7
Cash Quality
45

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 9 years · 34 quarters